foxy-5
Small moleculeexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT02020291)
Timeline
Indications
Mechanism of action
- WNT5ASupplementation
WNT5A supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CSCC[C@H](NC=O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O- Mol. weight
- 694.79 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297281 ↗
Also known as
- foxy-5
- foxy-5
- foxy-5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03883802 | Phase 2 | Apr 12, 2019 | BioVica AB, Catalan Institute of Oncology, SAGA diagnostics AB, SMS-Oncology BV, Unilabs A/S, WntResearch AB |
| NCT02655952 | Phase 1 | Apr 1, 2016 | Smerud Medical Research Denmark, WntResearch AB |
| NCT02020291 | Phase 1 | Jun 1, 2013 | WntResearch AB |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| WntResearch AB | For profit | 3 | 3 | 2 | 2013 |
| BioVica AB | For profit | 1 | 0 | 1 | 2019 |
| Catalan Institute of Oncology | Academic/Hospital | 1 | 0 | 1 | 2019 |
| SAGA diagnostics AB | For profit | 1 | 0 | 1 | 2019 |
| Smerud Medical Research Denmark | For profit | 1 | 0 | 1 | 2016 |
| SMS-Oncology BV | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Unilabs A/S | For profit | 1 | 0 | 1 | 2019 |
7 organizations
Page 1 / 1